A soluble form of ICAM-1 (sICAM-1) have been observed in normal human serum (Rothlein et al., J. Immunol. 147, 3788-3793) and at elevated levels in inflammatory and tumor bearing status (Seth et al., Lancet, 338, 83-84; Giavazzi et al., Canc. Res. 52, 2628-2630; Harning et al., Canc. Res., 51, 5003-5005). However, the mechanism to produce the sICAM-1 has been still unknown. In this report we presented evidence for the presence of the mRNA specifically encoding sICAM-1, which is probably generated by alternative splice donor site selection. A 19-base deletion occurred right upstream of the transmembrane region gave rise to reading frameshift and eliminate the entire transmembrane and cytoplasmic domains, resulting in incapability of ICAM-1 molecules to reside in the membrane. A reverse transcription-polymerase chain reaction (RT-PCR) using a primer pair specific to sICAM-1 revealed a positive expression in all tissues analyzed, though the amount and the ratio to the conventional species varied slightly from tissue to tissue. Inflammatory cytokines displayed a complex pattern in the ICAM-1 mRNA expression depending on the combination of cytokines and the cultured cell lines used.
No takes yet. Share an insight, caveat, or question.
Wakatsuki et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: